For years, the evidence linking PFAS contamination in drinking water to human health harm has accumulated primarily from laboratory studies, animal models, and epidemiological analyses of occupational exposure. The missing piece has been large-scale, clinical, community-based research directly documenting health outcomes in everyday Americans living with PFAS in their tap water. That piece has now arrived.
The Agency for Toxic Substances and Disease Registry (ATSDR) published results from its landmark Multi-Site PFAS Health Study in June 2026 — the largest clinical investigation ever conducted in United States communities with PFAS-contaminated drinking water. The study enrolled adults aged 18 and older and children aged 4 to 17 from eight sites across California, Colorado, Massachusetts, Michigan, New Hampshire, New York, New Jersey, and Pennsylvania — communities with documented past or ongoing PFAS contamination of their drinking water. Participants underwent extensive clinical testing assessing cardiometabolic health, liver function, thyroid function, kidney function, blood sugar regulation, and immune system parameters. Children also received neurobehavioral assessments.
The study is the culmination of a data collection effort that ran from 2019 through 2023 — and its publication arrives at a moment when the same EPA that inherited this research is proposing to roll back the drinking water standards designed to prevent further PFAS exposure.
What the Study Found and Why It Matters
The ATSDR multi-site study is a methodological landmark because it moved beyond associations observed in insurance claims data, occupational cohorts, or national survey data — it physically examined people, drew blood, tested urine, assessed thyroid scans, and directly measured PFAS concentrations in the serum of both adults and children living in contaminated communities.
Across the eight sites, researchers found elevated PFAS serum levels consistent with drinking water exposure. These elevated levels were systematically associated with the health outcomes documented in prior research: thyroid hormone disruption, liver enzyme elevations indicative of early hepatotoxicity, altered immune cell counts and reduced vaccine antibody response, glycemic irregularities, and elevated blood pressure — particularly among adults.
In children, the neurobehavioral assessments documented changes consistent with previous literature on PFAS effects on developing nervous systems — including attention, executive function, and processing speed measures that showed modest but statistically significant differences between higher-PFAS and lower-PFAS exposure groups.
Critically, the ATSDR study confirms that PFAS health effects are not limited to the highest-exposure occupational workers or communities adjacent to single contamination point sources — they are present and measurable in a cross-section of ordinary American communities across eight different states, at exposure levels consistent with what UCMR 5 testing is now documenting in 176 million Americans' tap water.
The Juxtaposition with the EPA's Proposed Rollback
The EPA has proposed rolling back enforceable drinking water limits for four PFAS chemicals — GenX, PFHxS, PFNA, and PFBS — and extending compliance deadlines for PFOA and PFOS. The ATSDR study provides the clearest population-based clinical evidence yet that PFAS exposure at the concentrations found in community drinking water produces measurable harm. That this evidence is being published as federal protections are being withdrawn creates one of the most direct science-to-policy tensions in contemporary American public health.
Public health advocates and researchers have called for the public comment process — open until July 20, 2026 — to receive submissions from community members, healthcare providers, and scientists. The July 7, 2026 public hearing provides an opportunity for affected communities to present testimony. The ATSDR study findings can be submitted as scientific evidence in support of maintaining stronger protections.
For the communities that participated in the study — and for the tens of millions of Americans whose tap water contains detectable PFAS at concentrations that would now go unregulated under the proposed EPA rule — the message from this research is direct: the damage is real, it is measurable, and it is happening right now.
Frequently Asked Questions
Q: What is the ATSDR multi-site PFAS study, and why is it significant?
A: It is the largest US clinical study ever conducted of health outcomes in communities with PFAS-contaminated drinking water. It enrolled adults and children from 8 sites across 8 states, directly measuring PFAS serum levels alongside clinical health markers, including liver, thyroid, kidney, immune, cardiometabolic, and neurobehavioral assessments.
Q: What health effects were found in PFAS-exposed community residents?
A: Thyroid hormone disruption, liver enzyme elevations, altered immune function and reduced vaccine antibody response, glycemic irregularities, elevated blood pressure in adults, and modest but significant neurobehavioral differences in children.
Q: Are these findings new?
A: The specific associations are consistent with prior research. What is new is the scale: this is the largest clinical study ever of PFAS health effects in everyday American drinking water communities — confirming real-world community-level harm rather than occupational or animal model data.
Q: What can affected communities do right now?
A: Submit comments on the EPA's proposed PFAS rollback rules through July 20, 2026. Attend or register for the July 7 public hearing. Install certified point-of-use reverse osmosis or NSF/ANSI 58 filters for drinking water. Advocate for local water utility testing under UCMR 5.
Q: How does this study relate to the EPA's proposed rollbacks?
A: The study's findings directly demonstrate health damage in communities with the same PFAS exposure levels that the EPA's proposed rollbacks would leave unregulated — creating a direct tension between published federal science and federal regulatory policy.
